Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin controlled release - HanAll Biopharma

Next Previous
Drug Profile

Metformin controlled release - HanAll Biopharma

Alternative Names: Glucodown OR; Glucodown OR sustained-release tablets - HanAll; HL-018; HL001; HL002; Metformin 500mg + 750mg optimised release tablets - HanAll; Metformin OR tablets - HanAll

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HanAll Biopharma
  • Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus
  • Discontinued Obesity

Most Recent Events

  • 23 Feb 2023 Discontinued - Preclinical for Obesity in South Korea (PO) (HanAll Biopharma pipeline, February 2023)
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Obesity in South Korea (PO)
  • 30 Oct 2018 HL 018 is still in preclinical trials for Obesity in South Korea (Hanall Biopharma pipeline, October 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top